Does Ozempic Work for Weight Loss? Clinical Evidence & Genetics

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, Ozempic (semaglutide) does produce measurable weight loss in clinical studies, with participants losing 10-15% of baseline body weight over 68 weeks in the SUSTAIN-6 trial. However, efficacy varies significantly between individuals based on metabolic, genetic, and lifestyle factors.

Understanding whether GLP-1 therapy works for you requires more than headlines. PlexusDx helps patients evaluate clinical evidence alongside personal biomarkers and genetic predispositions to determine if this treatment class aligns with their unique metabolic profile and weight management goals.

Clinical Evidence: What the Research Actually Shows

Multiple randomized controlled trials demonstrate Ozempic's efficacy for weight loss. The SUSTAIN-6 trial showed 13.8% weight reduction at 68 weeks in Type 2 diabetes patients receiving 1.0 mg weekly semaglutide. The SELECT trial with Wegovy (higher-dose semaglutide for weight loss) documented 17.4% reduction in non-diabetic adults.

However, response rates are heterogeneous. Approximately 25-35% of participants in clinical trials experience minimal weight loss, highlighting that GLP-1 therapy is not universally effective. Provider discussions should address individual baseline characteristics, comorbidities, and concurrent lifestyle factors affecting outcomes.

How Genetic Factors Shape Individual GLP-1 Response

Your genetic makeup influences GLP-1 pathway sensitivity through variants in key receptor and metabolic genes. The GLP1R rs6923761 polymorphism, FTO rs9939609, MC4R rs17782313, and GIPR rs1800437 variants are associated with differences in appetite regulation, satiety signaling, and baseline weight susceptibility. These predispositions may help explain why some individuals achieve substantial weight loss while others show limited response to the same medication and dose.

Genetic Variant	Gene Function	Clinical Context
GLP1R rs6923761	GLP-1 receptor sensitivity	May influence satiety and appetite suppression response to GLP-1 agonists
GIPR rs1800437	Glucose-dependent insulinotropic peptide receptor	Associated with baseline weight predisposition and dual-peptide therapy response
FTO rs9939609	Fat mass and obesity associated	Linked to intrinsic obesity risk and metabolic rate; variant carriers may show different baseline treatment response
MC4R rs17782313	Melanocortin-4 receptor signaling	Influences appetite centers in the brain and individual weight loss trajectory on GLP-1 therapy

Biomarkers That Predict Treatment Suitability

Beyond genetics, metabolic biomarkers help contextualize whether GLP-1 therapy is appropriate. Fasting insulin, HbA1c, C-reactive protein, and lipid panels reveal underlying insulin resistance, glucose dysregulation, and inflammatory status. Individuals with elevated fasting insulin or significant insulin resistance often show robust GLP-1 response, as the medication directly addresses the pathophysiology.

Conversely, patients with normal fasting insulin, well-controlled glucose, and minimal metabolic inflammation may achieve only modest weight loss from semaglutide alone. In these cases, provider conversations should explore whether dual-peptide compounds, intensive lifestyle modification, or alternative therapies better align with metabolic phenotype and goals.

Who Benefits Most and Safety Considerations

GLP-1 therapy is most effective in individuals with Type 2 diabetes, significant insulin resistance, BMI above 30 kg/m², or documented prediabetes with metabolic dysfunction. Those with baseline appetite dysregulation or emotional eating patterns often respond favorably due to the medication's direct effect on appetite centers. Pregnant individuals, those with personal history of medullary thyroid cancer or multiple endocrine neoplasia type 2, and certain gastrointestinal conditions require cautious evaluation.

Adverse effects—nausea, vomiting, constipation, and potential pancreatitis risk—warrant screening. A qualified healthcare provider should review your full medical history, medications, and surgical history before initiating any GLP-1 therapy. Compounded semaglutide and tirzepatide formulations from licensed 503A pharmacies undergo rigorous quality verification but are not FDA-branded products and require ongoing provider supervision.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context for how your body's GLP-1 and appetite-regulation pathways respond to this medication class. Testing for variants in GLP1R, GIPR, FTO, and MC4R can support conversations with your provider about expected response rates, optimal dosing strategies, and whether combination therapy or alternative approaches may suit your genetic predispositions better than single-agent semaglutide.

The test reveals predispositions in peptide metabolic pathways—not an exact prediction of medication response or weight loss magnitude. Individual outcomes depend on medication adherence, dose titration, lifestyle factors, comorbidities, and how your unique genetic background interacts with environmental and behavioral variables. Genetic insights should always be interpreted alongside clinical evaluation and metabolic biomarkers.

Understanding your genetic profile and metabolic foundation empowers more precise conversations with your provider about GLP-1 formulation choice, combination protocols, and realistic outcome expectations. PlexusDx compounded semaglutide, tirzepatide, and dual-peptide options can be tailored in partnership with your healthcare team once you have clarity on your individual treatment suitability.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at from $209/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.